Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Radionuclides which decay by the emission of alpha-particles are attractive for certain radioimmunotherapeutic applications. These include the treatment of lymphomas, compartmentally spread malignancies such as ovarian cancer and neoplastic meningitis, and micrometastatic disease. Two alpha-emitting radionuclides of interest for this purpose are 212Bi (60.6 min half life) and 211At (7.2 hr half life). Compared with the beta-emitters commonly used for radiotherapy, the alpha-particles of 212Bi and 211At are of higher energy, much shorter range (less than 100 microm), and considerably higher linear energy transfer. Preliminary results obtained in a variety of in vitro systems and in vivo models have documented the exquisite toxicity of alpha-particles and have established a basis for initiating radiotherapy trials in humans with monoclonal antibodies labeled with alpha-emitting radionuclides.
Zalutsky
M R
MR
Department of Radiology, Duke University Medical Center, Durham, NC, USA.
Bigner
D D
DD
D000512:Alpha Particles / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001246:Astatine / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D018499:Linear Energy Transfer; D008223:Lymphoma / Q000532:radiotherapy; D008581:Meningitis / Q000209:etiology / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D016499:Radioimmunotherapy / Q000379:methods; D011868:Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D011868:Radioisotopes; D001729:Bismuth; D001246:Astatine